Human medicines European public assessment report (EPAR): Tepmetko, tepotinib, Date of authorisation: 16/02/2022, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Tepmetko, tepotinib, Date of authorisation: 16/02/2022, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Livmarli, maralixibat chloride, Date of authorisation: 09/12/2022, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Livmarli, maralixibat chloride, Date of authorisation: 09/12/2022, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Atriance, nelarabine, Date of authorisation: 22/08/2007, Revision: 30, Status: Authorised

Human medicines European public assessment report (EPAR): Atriance, nelarabine, Date of authorisation: 22/08/2007, Revision: 30, Status: Authorised

Human medicines European public assessment report (EPAR): Steqeyma, ustekinumab, Date of authorisation: 22/08/2024, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Steqeyma, ustekinumab, Date of authorisation: 22/08/2024, Revision: 9, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness